UKCA Mark for LVOne Stroke Test, LT 3001 24-Hour Window, and Leaky Core Imaging

Stroke care is advancing on multiple fronts: Upfront Diagnostics has received a UKCA mark for its LVOne Rapid Stroke Blood Test, a phase 2 international study showed the investigational drug LT 3001 can be given up to 24 hours after stroke symptom onset, and new research in the journal Stroke introduces a "leaky core" imaging concept to assess blood-brain barrier disruption.

Upfront Diagnostics said it has received a UKCA mark for its LVOne Rapid Stroke Blood Test and has partnered with the London Ambulance Service (LAS), which will use the lateral flow test to identify patients likely experiencing a severe stroke while in the ambulance. By triaging patients with large vessel occlusion (LVO) strokes, they can be rerouted to specialist centers capable of performing mechanical thrombectomies, a procedure that removes large clots from brain arteries. The Cambridge, UK-based company's CEO said that garnering a UKCA mark is a "major milestone" for the firm, which he cofounded in 2017. Approximately 280 vehicles will be equipped, serving north central, northwest, and northeast London and covering a population of about 6.5 million. During a six-month pilot, paramedics will test suspected patients using the test. LVOne measures two blood markers: D-dimer, associated with clot formation, and GFAP, associated with bleeding in the brain. The test, which relies on a fingerprick, has a turnaround time of about 10 minutes. The company is exploring additional clinical deployments beyond the current program and intends to have both UKCA and CE-IVD marks in place for LVOne by the first part of 2026, with a desire to submit the test to the US Food and Drug Administration following its de novo request pathway.

Separately, phase 2 results from an international study of a new drug called LT 3001, trade name odat, show the drug is safe and gives doctors and patients a bigger window for lifesaving treatment. The most common current drug, tPA, can only be given up to about four and a half hours after stroke symptoms, while investigators were able to give LT 3001 up to 24 hours after onset of stroke symptoms. The findings were presented by the medical director of Common Spirit Memorial Neuroscience Institute, who helped lead the study, and could make a big difference for patients living in the stroke belt.

In the imaging study, researchers reviewed 291 post-stroke brain scans and could see and study areas affected by blood-brain barrier disruption, also known as a leaky core. This disruption — where the walls of blood vessels in the brain become more permeable or flexible and can start to break down or leak — is believed to signal underlying injury and inflammation and has served as a marker for increased risk of hemorrhage after an ischemic stroke. The algorithm is generated from existing MRI scans taken after a person experiences a stroke, using information from a sequence that is already being collected as part of brain scans. Investigators found that for every 1% increase in blood-brain barrier disruption, the odds of a person having a poor outcome, such as requiring help with care or experiencing severe disability or death, three months after an ischemic stroke increased by 16%. The imaging could help tailor treatment plans, including decisions about thrombectomy, blood thinners, and clot-dissolving medication, and could identify patients who might benefit from treatment despite conventional imaging suggesting otherwise. Supported in part by the National Institutes of Health, the approach could also inform targeted clinical trials and help monitor adults who have had a stroke and have increased risks for post-stroke complications.

Experts speaking at a recent conference outlined a future of stroke care shaped as much by systems, equity, and prevention as by the next breakthrough drug or device. They reflected on how stroke care has evolved from a time when emergency clinicians had little to offer to one in which patients who once faced devastating outcomes could return to near-normal function within hours, but emphasized that transfer networks, emergency medical systems, and interhospital coordination must be as well-resourced and carefully designed as the therapies themselves. Equitable access remained paramount, with disparities in access representing the next major frontier. Factor XI inhibition was described as a potentially "radical" shift in second-stroke prevention, one that could reshape cardiovascular care more broadly if safety profiles held. There is also a growing emphasis on tissue-based decision-making rather than rigid time windows in hyperacute stroke, and greater use of advanced neuroimaging in the earliest phase of evaluation is expected to significantly influence diagnosis and treatment selection.

Speakers also called attention to knowledge gaps, including cryptogenic stroke, which can account for up to 30% of cases even after a comprehensive workup, and nontraditional and women-specific risk factors. A major unmet need exists in stroke recovery beyond the initial days of hospitalization, with long-term rehabilitation and survivorship needing to become central to future innovation. Technology may play an expanding role in that effort: one researcher presented research on a wearable device capable of measuring both the quantity and quality of daily social interactions, offering a way to identify and address social isolation during recovery, and another advocated for adapting the NIH Stroke Scale to better serve nonverbal and American Sign Language–using patients. The overall vision emerging from the conference suggested that the most meaningful changes ahead will integrate scientific breakthroughs with equitable delivery, personalized prevention, inclusive assessment, and sustained support for stroke survivors long after the acute event.